Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO
Antineoplastic Combined Chemotherapy Protocols
Carbon Dioxide
Colorectal Neoplasms
/ therapy
Combined Modality Therapy
Cytoreduction Surgical Procedures
Humans
Hyperthermia, Induced
Hyperthermic Intraperitoneal Chemotherapy
Mitomycin
/ therapeutic use
Peritoneal Neoplasms
/ drug therapy
Prognosis
Retrospective Studies
Survival Rate
Carcinomatosis
Colorectal cancer
HIPEC
HIPEC-CO2
Peritoneal metastasis
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
16
12
2020
accepted:
16
03
2021
pubmed:
31
3
2021
medline:
16
10
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO
Identifiants
pubmed: 33782856
doi: 10.1007/s13304-021-01034-2
pii: 10.1007/s13304-021-01034-2
doi:
Substances chimiques
Carbon Dioxide
142M471B3J
Mitomycin
50SG953SK6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1443-1448Informations de copyright
© 2021. Italian Society of Surgery (SIC).
Références
Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7:108–115
doi: 10.1038/nrclinonc.2009.217
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743
doi: 10.1200/JCO.2003.04.187
Yonemura Y, Canbay E, Ishibashi H (2013) Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J 2:978394
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27:681–685
doi: 10.1200/JCO.2008.19.7160
Quenet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F (2019) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis PRODIGE 7. Eur J Surg Oncol 45:e17
doi: 10.1016/j.ejso.2018.10.086
Ortega-Deballon P, Facy O, Jambet S, Magnin G, Cotte E, Beltramo JL, Chauffert B, Rat P (2010) Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann Surg Oncol 17:1957–1963
doi: 10.1245/s10434-010-0937-z
Sugarbaker PH, Averbach AM, Jacquet P, Stuart OA, Stephens AD (1996) Hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) with mitomycin C. Surg Technol Int 5:245–249
pubmed: 15858747
pmcid: 15858747
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42
doi: 10.1097/00000658-199501000-00004
Ceelen W (2019) HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol 45(3):400–402
doi: 10.1016/j.ejso.2018.10.542
Yurttas C, Fisher OM, Cortés-Guiral D, Haen SP, Königsrainer I, Königsrainer A, Beckert S, Liauw W, Löffler MW (2020) Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick? Memo 20:1–6
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surgical Oncol 18:1575–1581
doi: 10.1245/s10434-011-1631-5
Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder JM, Abboud K, Marchal F, Quenet F, Goere D (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37:2028–2040
doi: 10.1200/JCO.18.01688
Hompes D, D’Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V (2014) The use of oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 109:527–532
doi: 10.1002/jso.23546
Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179:e133–e139
doi: 10.1016/j.jss.2012.01.015
Silva CR, Ruiz FJ, Estévez IB, Campos JC, García AT, López MR, Poveda IG, Mata JA, Velasco SM, Santoyo JS (2017) Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study. World J Surg Oncol 15:1–8
doi: 10.1186/s12957-016-1068-1
Sánchez-García S, Villarejo-Campos P, Padilla-Valverde D, Amo-Salas M, Martín-Fernández J (2016) Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO
doi: 10.3109/02656736.2016.1152515
Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M (2008) Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 63:389–395
doi: 10.1111/j.1365-2044.2007.05380.x
Facy O, Combier C, Poussier M, Magnin G, Ladoire S, Ghiringhelli F, Chauffert B, Rat P, Ortega-Deballon P (2015) High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery 157:72–78
doi: 10.1016/j.surg.2014.06.006
Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J (2015) Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol 1:10–23
Bhatt A (2018) Management of peritoneal metastases-cytoreductive surgery, HIPEC and beyond. Springer, p 79
doi: 10.1007/978-981-10-7053-2
Benoit L, Cheynel N, Ortega-Deballon P, Di Giacomo G, Chauffert B, Rat P (2008) Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surgical Oncol 15:542–546
doi: 10.1245/s10434-007-9635-x
Sánchez-García S, Padilla-Valverde D, Villarejo-Campos P, Martín-Fernández J, García-Rojo M, Rodríguez-Martínez M (2014) Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO
doi: 10.1016/j.surg.2013.12.005
Cianci S, Vizzielli G, Fagotti A, Pacelli F, Di Giorgio A, Tropea A, Biondi A, Scambia G (2018) A novel HIPEC technique using hybrid CO 2 recirculation system: intra-abdominal diffusion test in a porcine model. Updates Surg 70:529–533
doi: 10.1007/s13304-018-0557-x
Padilla-Valverde D, Sanchez-Garcia S, García-Santos E, Marcote-Ibañez C, Molina-Robles M, Martín-Fernández J, Villarejo-Campos P (2017) Usefulness of thermographic analysis to control temperature homogeneity in the development and implementation of a closed recirculating CO
doi: 10.1080/02656736.2016.1237679